TMCnet News

B-Cell Maturation Antigen (BCMA) Market Report 2016 - Hot Target for Emerging Treatment Modalities - Research and Markets

[September 19, 2016]

B-Cell Maturation Antigen (BCMA) Market Report 2016 - Hot Target for Emerging Treatment Modalities - Research and Markets

Research and Markets has announced the addition of the "B-Cell Maturation Antigen (BCMA): Hot Target for Emerging Treatment Modalities" report to their offering.

The highly restricted expression of B-cell maturation antigen (BCMA) to plasma cells and its role in the survival and growth for multiple myeloma cells makes BCMA a good potential target for enhanced immunotherapeutic strategies.

This report describes and analyzes the:

- Scientific rationale for BCMA-targeted therapies;

- Preclinical proof-of-concept of BCMA blockade;

- Clinical experience with BCMA-targeted therapies;

- The competitive landscape of BCMA-targeted treatment modalities;

- Profiles of anti-BCMA CAR T-cells, antibody-drug conjugate and T-cell redirecting bispecific antibodies:

- Profiles of companies involved in develpment of anti-BCMA therapy candidates.

Especially activity-enhanced antibodies and cells such as antibody-drug conjugates (ADCs) and T-cell redirecting bispecific antibodies as well as chimeric antigen receptor (CAR) T-cells, respectively, will benefit from the high target selectivity of BCMA to avoid on-target, off-tumor toxicity.

As a consequence, novel cellular and humoral BCMA-targeted treatment modalities have emerged and resulting product candidates entered first-in-human clinical evaluation. Further development candidates are undergoing IND-enabling studies.

Key Topics Covered:

1. Target (News - Alert) Background

2. Target Antigen Expression Profile

3. Preclinical Proof-of-Concept

4. Clinical Indications & Treatment Options

5. Clinical Experience with BCMA-Targeted Treatment Modalities

6. Treatment Modalities & Competitive Landscape

7. Drug & Cell Therapy Candidate Profiles

7.1. CAR T-Cells

7.2. Antibody-Drug Conjugate (ADC (News - Alert))

7.3. T-Cell Redirecting Antibodies

8. Company Profiles

9. References

For more information about this report visit http://www.researchandmarkets.com/research/xjv638/bcell_maturation